Brainomix Secures $18M to Expand AI Imaging Technology

Brainomix has completed a £14 million ($18 million) Series C funding round, announced in a press release. The funding will support the company's expansion of its AI imaging technology in healthcare, particularly in the US market.

The investment round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund, with new participation from Hostplus via the IP Group Hostplus Innovation Fund. This financial boost will enable Brainomix to accelerate the commercial expansion of its Brainomix 360 Stroke platform, which has already been deployed in over 300 hospitals and has significantly improved treatment rates for stroke patients.

In addition to stroke imaging, Brainomix is advancing its AI technology in lung fibrosis. The company has developed the Brainomix 360 e-Lung technology, which has received FDA clearance and aims to enhance the diagnosis and treatment of lung fibrosis. The new funding will also support the clinical uptake of this technology.

Brainomix, a University of Oxford spinout, operates in more than 20 countries and plans to expand its operations and global commercial team further. The company continues to leverage its position as a European market leader to improve patient care and access to life-saving therapies.